Sanofi and Regeneron Pharmaceuticals got effective results in reducing the risk of major adverse heart events in a clinical study of nearly 19,000 patients with the help of cholesterol drug Praluent. Drugmakers now hope that the results are good enough to convince insurers to pay for the pricey medicine. Treatment with Praluent was associated with fewer overall deaths, cutting down the risk of overall mortality by up to 15% as compared to the patients who received statin therapy. For improving the commercial scenario of the drug Sanofi and Regeneron showed willingness to reduce the net price of Praluent for certain high-risk patients only if U.S. payers agree to ease the restrictions that have so far limited access to the drug. Regeneron and Sanofi mentioned that they are planning to file a supplementary Biologics License Application to FDA by the mid of this year in hopes of adding the Odyssey data to Praluent’s label.
DelveInsight Blog

Assessing the Growing Role & the Dema...
May 11, 2022
Over the past few years, the prevalence of the chronic disease has grown significantly. The rising prevalence is lead...

Can Dupixent Be A Gamechanger In The Atopi...
Mar 25, 2022
Dupixent (dupilumab) is a non-immunosuppressive fully human monoclonal antibody that inhibits the signalling of the i...

Assessment of Key Products that Got FDA Ap...
Jan 05, 2022
Although COVID-19 continued to dominate headlines in 2021, pharmaceutical companies did not cease developing new trea...
Sign Up and Stay Informed
Penetrative insights and rich analysis of Pharma, Biotech and MedTech space.
Editor's Pick
Commercial Roadmap for the Launch: What can Biopharmaceuticals do to Increase...
The Pharma and Biotech Healthcare market has been an ever-changing industry in terms of...
Emerging Market for Organ on a Chip
The organ on a chip is a microfluidic culture device that recapitulates the complicated...
Global Top Players in Intraocular Lens (IOL) Market
An Intraocular Lens implant is a synthetic, artificial lens placed inside the eye...
Investigating the Pipeline for Ankylosing Spondylitis Treatment Landscape
Ankylosing Spondylitis is a form of arthritis that primarily affects the spine. It caus...
LAG 3: A Promising Next Generation Cancer Immunotherapy
Immunotherapy also called biologic therapy, is a type of cancer treatment that boosts t...
RECENT ARTICLES